Kevin Millwood leaves Red Sox organization

7 Comments

According to Maureen Mullen of CSNNE.com, veteran right-hander Kevin Millwood cleaned out his locker at Triple-A Pawtucket on Saturday and has suddenly left the Red Sox organization.

Millwood signed a minor league contract with Boston in the middle of May after opting out of a similar pact with the Yankees. He was hoping that the Red Sox would allow him quicker passage to the major leagues, but May turned to June and June turned to July. And now it’s August. Still no promotion.

Millwood, 36, will likely aim to sign another minor league deal with a different team. He has posted a 4.32 ERA and 76/31 K/BB ratio in 89 2/3 innings this year in the minors, primarily at the Triple-A level.

Millwood finished 4-16 with a 5.10 ERA and 1.51 WHIP over 31 starts for the Orioles last season.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.